13F Holdings
中文EN

AGEN AGENUS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1098972 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.4%
TTM net income YoY187.7%
TTM EPS YoY114.6%
Revenue 3-yr CAGR9.9%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin38.9%
Net margin23.0%
FCF margin-77.5%
EBITDA margin40.6%

Returns

ROE—
ROA12.9%
ROIC (approx.)—
Asset turnover0.56x

Leverage & solvency

Liabilities / assets145.7%
Debt / equity—
Current ratio0.73x
Interest coverage0.85x

Cash quality & payout

Operating cash flow / net income-3.37x
Accruals ratio56.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$114.20M$103.46M$156.31M$98.02M$295.67M
Cost of revenue$1.02M$486,000$3.11M$10.57M$3.47M
Gross profit$113.17M$102.98M$153.20M$87.46M$292.19M
R&D expense$79.34M$155.53M$234.57M$186.69M$178.61M
SG&A expense$54.39M$71.88M$78.74M$81.01M$76.36M
Operating income-$20.17M-$120.47M-$159.55M-$179.43M$25.75M
Interest expense$55.62M$120.42M$103.86M$64.12M—
Pretax income-$3.08M-$232.27M-$257.44M——
Income tax$0$0$0$0$0
Net income$115,000-$227.21M-$245.76M-$220.07M-$23.93M
EBITDA-$10.17M-$107.13M-$145.96M-$172.48M$32.53M
EPS (basic)0.00-10.59-13.75-15.64-0.11
EPS (diluted)0.00-10.59-13.75-15.64-0.11
Weighted avg. shares (diluted)29.73M21.47M17.89M14.09M228,919
Balance sheet
Cash & equivalents$3.00M$40.44M$76.11M$178.67M$291.93M
Short-term investments$0——$14.68M$14.99M
Receivables$1.83M$407,000$25.84M$2.74M$1.52M
Current assets$133.44M$45.57M$112.42M$213.12M$331.97M
PP&E, net$15.47M$120.09M$133.42M$133.02M$60.03M
Goodwill$24.09M$24.09M$24.72M$25.47M$24.88M
Intangibles$3.04M$3.38M$4.41M$6.23M$8.49M
Total assets$226.80M$226.27M$313.91M$413.56M$465.96M
Current liabilities$323.49M$221.40M$255.90M$188.95M$156.94M
Short-term debt$44.66M$2.70M$146,000$575,000$728,000
Long-term debt$0$30.47M$12.77M$12.58M$12.82M
Total debt$44.66M$33.17M$12.91M$13.16M$13.55M
Total liabilities$504.66M$532.70M$462.30M$468.46M$418.05M
Shareholders' equity-$271.11M-$326.38M-$160.33M-$61.28M$34.44M
Net debt$41.66M-$7.27M-$63.20M-$165.51M-$278.38M
Shares outstanding35.32M23.63M19.72M——
Cash flow statement
Operating cash flow-$77.19M-$158.31M-$224.20M-$175.37M$10.14M
Capital expenditure$6,000$576,000$9.95M$53.06M$33.81M
Free cash flow-$77.20M-$158.89M-$234.16M-$228.44M-$23.67M
Investing cash flow$1.19M$27,000$3.40M-$33.61M-$43.15M
Financing cash flow$36.59M$122.84M$119.87M$95.83M$225.26M
Depreciation & amortization$10.00M$13.34M$13.59M$6.95M$6.79M
Stock-based compensation$13.77M$17.39M$22.87M$18.34M$19.58M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.